Artigo Produção Nacional Revisado por pares

Ethanolic extract of Erythrina velutina Willd ameliorate schizophrenia-like behavior induced by ketamine in mice

2018; De Gruyter; Volume: 16; Issue: 2 Linguagem: Inglês

10.1515/jcim-2018-0038

ISSN

2194-6329

Autores

Naiara Coelho Ximenes, Manuel Alves Dos Santos Júnior, Germana Silva Vasconcelos, Kátia Cilene Ferreira Dias, Mércia Marques Jucá, Aline Holanda Silva, Luzia Kalyne Almeida Moreira Leal, Glauce Socorro Barros Viana, Francisca Cléa Florenço de Sousa, Silvânia Maria Mendes Vasconcelos,

Tópico(s)

Stress Responses and Cortisol

Resumo

Background Schizophrenia is a chronic mental disorder, characterized by positive, negative and cognitive symptoms. In general, several plants have shown activity in diseases related to the central nervous system (e.g., Erythrina velutina (EEEV), also known as "mulungu"). For this reason, we aimed to investigate the effects of standardized ethanol extract obtained from the stem bark of EEEV on the schizophrenia-like behaviors induced by ketamine (KET) administration. Methods Swiss mice were treated with KET (20 mg/kg, i.p.) or saline for 14 days. In addition, from 8th to 14th days, saline, EEEV (200 or 400 mg/kg, p.o.) or olanzapine (OLAN 2 mg/kg, p.o.) were associated to the protocol. On the 14th day of treatment, schizophrenia-like symptoms were evaluated by the prepulse inhibition of the startle reflex (PPI), locomotor activity evaluated by the open field test (OFT), spatial recognition memory evaluated by the Y-maze task and social interaction test (SIT). Results KET has caused deficits in PPI, and it has also has caused hyperlocomotion in OFT and deficits in SIT as compared to control. EEEV in both doses used, reversed behavioral changes induced by KET, likewise results obtained with the administration of OLAN. Conclusions Taken together, the results demonstrate that the standard extract of EEEV was able to revert schizophrenia-like symptoms, due to the administration in repeated doses of ketamine. Thus, our findings lead to a new perspective for the use of EEEV an interesting alternative for drug discovery in schizophrenia.

Referência(s)